Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

EB613, the first oral anabolic (bone building) peptide tablet for postmenopausal women with osteoporosis – Phase 3 protocol submitted with FDA feedback expected imminently; incremental data submitted to ENDO2026 and ASBMR

Entera Bio (ENTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Entera Bio Ltd. (ENTX) Discusses Osteoporosis Treatment Landscape and Clinical Potential of EB613 Oral Tablet Transcript

In a virtual Key Opinion Leader (KOL) roundtable hosted today, Entera Bio (Nasdaq: ENTX) convened globally recognized authorities in osteoporosis and women's health to discuss the current osteoporosis treatment landscape and the opportunity for its lead clinical candidate, EB613 - being developed as the first and only oral anabolic (bone-forming) tablet for osteoporosis.

TEL AVIV, Israel, April 14, 2026 (GLOBE NEWSWIRE) -- TEL AVIV, Israel, April 14, 2026 -- Entera Bio Ltd. (Nasdaq: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced it will host a virtual Key Opinion Leader (KOL) webinar focused on the osteoporosis treatment landscape and the opportunity for its lead clinical candidate, EB613 (oral PTH (1-34) tablet), on Monday, April 20, 2026 at 11:00 AM Eastern Time.

MIAMI, April 6, 2026 /PRNewswire/ -- Global law firm Greenberg Traurig, P.A. advised Israel-based Entera Bio Ltd.

TEL AVIV, Israel, April 02, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (Nasdaq: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced that it has entered into a securities purchase agreement for a private placement (the “Private Placement”) led by funds affiliated with BVF Partners L.P. (“BVF”).